Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.

DCPH

Deciphera Pharmaceuticals (DCPH)

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:DCPH
DataOraFonteTitoloSimboloCompagnia
14/06/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:DCPHDeciphera Pharmaceuticals Inc
12/06/202402:51Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:DCPHDeciphera Pharmaceuticals Inc
11/06/202423:18Edgar (US Regulatory)Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendmentsNASDAQ:DCPHDeciphera Pharmaceuticals Inc
11/06/202423:02Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:DCPHDeciphera Pharmaceuticals Inc
11/06/202423:01Edgar (US Regulatory)Form POSASR - Post-effective Amendment to an automatic shelf registration statementNASDAQ:DCPHDeciphera Pharmaceuticals Inc
11/06/202415:25Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:DCPHDeciphera Pharmaceuticals Inc
11/06/202415:18Edgar (US Regulatory)Form SC 14D9/A - Solicitation, recommendation statements: [Amend]NASDAQ:DCPHDeciphera Pharmaceuticals Inc
11/06/202415:15Edgar (US Regulatory)Form SC TO-T/A - Tender offer statement by Third Party: [Amend]NASDAQ:DCPHDeciphera Pharmaceuticals Inc
03/06/202413:00Business WireDeciphera Pharmaceuticals Announces Oral Presentation of Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the 2024 ASCO Annual Meeting and Online Publication in The LancetNASDAQ:DCPHDeciphera Pharmaceuticals Inc
13/05/202412:32Edgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:DCPHDeciphera Pharmaceuticals Inc
13/05/202412:31Edgar (US Regulatory)Form SC TO-T - Tender offer statement by Third PartyNASDAQ:DCPHDeciphera Pharmaceuticals Inc
10/05/202413:27Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:DCPHDeciphera Pharmaceuticals Inc
06/05/202423:16Edgar (US Regulatory)Form SC TO-C - Written communication relating to an issuer or third partyNASDAQ:DCPHDeciphera Pharmaceuticals Inc
29/04/202413:00Business WireDeciphera Pharmaceuticals to be Acquired by ONO Pharmaceutical For $2.4 BillionNASDAQ:DCPHDeciphera Pharmaceuticals Inc
09/04/202413:00Business WireDeciphera Pharmaceuticals to Present at the Stifel 2024 Virtual Targeted Oncology ForumNASDAQ:DCPHDeciphera Pharmaceuticals Inc
27/02/202413:00Business WireDeciphera Pharmaceuticals to Participate in Upcoming Investor ConferencesNASDAQ:DCPHDeciphera Pharmaceuticals Inc
14/02/202422:06Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:DCPHDeciphera Pharmaceuticals Inc
07/02/202413:52Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:DCPHDeciphera Pharmaceuticals Inc
07/02/202413:11Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:DCPHDeciphera Pharmaceuticals Inc
06/02/202413:00Business WireDeciphera Pharmaceuticals Announces Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:DCPHDeciphera Pharmaceuticals Inc
01/02/202422:50Business WireDeciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2023 Financial Results and Host Conference Call and Webcast on February 6, 2024NASDAQ:DCPHDeciphera Pharmaceuticals Inc
01/02/202413:00Business WireDeciphera Pharmaceuticals to Present at the Guggenheim Healthcare Talks 6th Annual Biotechnology ConferenceNASDAQ:DCPHDeciphera Pharmaceuticals Inc
18/01/202417:13Business WireDeciphera Pharmaceuticals Presents Long-Term Follow-Up Results from INTRIGUE Phase 3 Clinical Study in Second-Line GIST Patients at the 2024 American Society of Clinical Oncology Gastrointestinal Cancers SymposiumNASDAQ:DCPHDeciphera Pharmaceuticals Inc
08/01/202413:00Business WireDeciphera Pharmaceuticals Announces Planned 2024 Corporate Milestones Supporting Evolution to a Self-Sustaining, Multi-Product CompanyNASDAQ:DCPHDeciphera Pharmaceuticals Inc
05/01/202413:00Business WireDeciphera Pharmaceuticals Announces Nature Medicine Publication of Results from Exploratory ctDNA Analysis from INTRIGUE Phase 3 Study Demonstrating Substantial Clinical Benefit of QINLOCK® in 2L GIST Patients with Mutations in KIT Exon 11 and 17/18NASDAQ:DCPHDeciphera Pharmaceuticals Inc
02/01/202413:00Business WireDeciphera Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:DCPHDeciphera Pharmaceuticals Inc
01/12/202300:05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:DCPHDeciphera Pharmaceuticals Inc
29/11/202313:00Business WireDeciphera Pharmaceuticals to Present at the JMP Securities Hematology and Oncology SummitNASDAQ:DCPHDeciphera Pharmaceuticals Inc
30/10/202312:01Business WireDeciphera Pharmaceuticals Announces Third Quarter 2023 Financial ResultsNASDAQ:DCPHDeciphera Pharmaceuticals Inc
30/10/202312:00Business WireDeciphera Pharmaceuticals Announces Positive Top-line Results from MOTION Pivotal Phase 3 Study of Vimseltinib in Patients with Tenosynovial Giant Cell Tumor (TGCT) and Updated Results from Phase 1/2 Study of Vimseltinib in TGCTNASDAQ:DCPHDeciphera Pharmaceuticals Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:DCPH

La tua Cronologia

Per accedere al tempo reale push di Borsa è necessario registrarsi.

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network